Strike price

Coinbase Ventures and Chapter One Take Significant Share of ShapeShift DAO's New FOX Success Tokens

Retrieved on: 
Thursday, March 24, 2022
Bitcoin, Ethereum, Decentralized finance, Organization, NEW, UMA, Investment, FOX, Chapter One, Growth, Success, Web3, ShapeShift, DAO, Ecosystem, Strike, Daos, Strike price, USDC, History, Cryptocurrency, Uniswap

DENVER and NEW YORK, March 24, 2022 /PRNewswire/ -- ShapeShift DAO, a decentralized, non-custodial cryptocurrency platform, and UMA, an Optimistic Oracle that validates data for Web3 protocols, announced today the strategic investment by Coinbase Ventures and Chapter One in a significant portion of the ShapeShift DAO's recently minted FOX Success Tokens. These investments mark a marquee mobilization of Success Tokens in general, and the FOX Success Token in specific, with large, stable investment organizations.

Key Points: 
  • These investments mark a marquee mobilization of Success Tokens in general, and the FOX Success Token in specific, with large, stable investment organizations.
  • "We're honored to have strategic investors Coinbase Ventures and Chapter One aligned with the success of ShapeShift DAO," said Willy Ogorzaly, head of decentralization for the ShapeShift DAO.
  • "We believe Success Tokens are a unique way to align incentives and ensure that we are supporting ShapeShift in their growth.
  • The Strike Price for the Fox Success Token is $0.8 FOX/USD, and each Success Token is backed by 2 FOX.

HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 23, 2021
Options, Strike price, Exercise

These stock option awards have exercise prices of $5.85 and $5.42 per share, respectively, reflecting HTGs closing trading price on the grant date.

Key Points: 
  • These stock option awards have exercise prices of $5.85 and $5.42 per share, respectively, reflecting HTGs closing trading price on the grant date.
  • Each stock option has a 10-year term and is subject to the terms and conditions of HTGs 2021 Inducement Plan, adopted by HTGs Board of Directors on July 1, 2021, and its standard form of agreement for inducement grants of nonstatutory stock options.
  • HTG is focused on NGS-based molecular profiling.
  • The companys proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.

Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Finance, Financial markets, Money, Options, Contract law, Corporate finance, Equity securities, Short, Stock, Strike price, NASDAQ

The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The option has an exercise price of $19.12 per share, which is equal to the closing price of Sierras common stock on the date of grant.
  • The option is subject to the terms and conditions of Sierras 2018 Equity Inducement Plan, and the terms and conditions of the stock option agreement covering the grant.
  • Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, June 29, 2021
Adjuvants, Health sciences, Health, Medical specialties, Immunologic adjuvant, Strike price, Option, VLA2001

The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock option was granted with an exercise price of $9.29 per share, which is equal to the closing price of Dynavax common stock on the date of grant, and was provided as a material inducement to Mr. Slebir's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The option is subject to the terms and conditions of a stock option agreement covering the grant and Dynavax's 2021 Inducement Award Plan, which was adopted on January 9, 2021 and provides for the granting of stock options to new employees.
  • Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines.
  • Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships.

DarioHealth Announces Closing of wayForward Acquisition

Retrieved on: 
Tuesday, June 8, 2021
Options, Private law, Law, Inheritance, Labour law, Property law, Vesting, NASDAQ, Strike price, Articles

The option will have an exercise price per share of $19.99 (the closing price of the Common Stock on the Nasdaq Stock Market on June 4, 2021, the trading day prior to the Closing date).

Key Points: 
  • The option will have an exercise price per share of $19.99 (the closing price of the Common Stock on the Nasdaq Stock Market on June 4, 2021, the trading day prior to the Closing date).
  • 60,000 of the option shares will vest over a three-year period beginning on the Closing date, subject to Mr. Singh's continued employment by the Company or its subsidiary on the applicable vesting date.
  • DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health.
  • To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com .

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, April 7, 2021
Options, Financial markets, Finance, Financial economics, Corporate finance, Stock market, Equity securities, Contract law, Stock, Strike price, Executive compensation, NASDAQ

Such stock option has an exercise price per share equal to $24.90, which was the closing trading price on April 5, 2021, the date of the grant.

Key Points: 
  • Such stock option has an exercise price per share equal to $24.90, which was the closing trading price on April 5, 2021, the date of the grant.
  • In addition, in connection with hiring a new employee, the compensation committee of the Companys board of directors granted the individual an option to purchase 30,000 ordinary shares of the Company.
  • Such stock option has an exercise price per share equal to $24.74, which was the closing trading price on April 1, 2021, the date of the grant.
  • The options were granted pursuant to the Companys 2020 Employment Inducement Incentive Plan, which was approved by the Companys board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 15, 2020
Biogen, Spinal muscular atrophy, Proskauer Rose, NASDAQ, Mano, Strike price, Kernel page-table isolation, Life sciences, Industries, Companies

NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel.

Key Points: 
  • NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel.
  • Prior to Biogen, Mr. Mano served as Senior Counsel at Proskauer Rose LLP.
  • The stock option was granted as an inducement material to Mr. Mano entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option has an exercise price of$15.57 per share, the closing price of Karyopharm's common stock on December 14, 2020.

Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 20, 2020
Biotechnology, Pharmaceutical, Health, Options, Financial economics, Finance, Money, Strike price, Exercise, Stock

The option has a per share exercise price of $13.40 USD, the closing trading price on November 13, 2020.

Key Points: 
  • The option has a per share exercise price of $13.40 USD, the closing trading price on November 13, 2020.
  • One-third of the shares underlying the option vest in November 2021, and the balance of the shares vest in a series of 24 equal monthly installments thereafter.
  • The inducement option was granted as an inducement material to the new employee entering into employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement stock option also has a ten-year term and is subject to the terms and conditions of the stock option agreement pursuant to which the option was granted.

IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 4, 2020
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Options, Financial markets, Finance, Corporate finance, Financial economics, Stock market, Contract law, Stock, Exercise, NASDAQ, Strike price

IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on May 1, 2020, the Company granted a newly hired, non-executive employee a non-statutory stock option to purchase 33,000 shares of the Companys common stock.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on May 1, 2020, the Company granted a newly hired, non-executive employee a non-statutory stock option to purchase 33,000 shares of the Companys common stock.
  • The stock option has an exercise price of $3.62 per share, equal to the closing price of IVERIC bios common stock on May 1, 2020.
  • The inducement grant is subject to the terms and conditions of an award agreement covering the grant and the Companys 2019 Inducement Stock Incentive Plan.
  • IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.

Pond Technologies Announces Filing Postponement of Annual and Interim Financial Statements and Related MD&A due to COVID-19 and Announces Grant of Stock Options

Retrieved on: 
Thursday, April 30, 2020
Options, Exercise, Strike price

Pond will be relying on this extension period due to delays experienced as result of COVID-19.

Key Points: 
  • Pond will be relying on this extension period due to delays experienced as result of COVID-19.
  • Pond is working diligently with its auditors to file the Annual Filings on or before June 15, 2020 and the Interim Filings on or before July 14, 2020.
  • In addition, on April 29, 2020, the Corporation approved the grant of an aggregate of 795,000 stock options under its stock option plan to certain of its officers and employees.
  • The options vest immediately, have an exercise price of $0.25 per share, and expire 5 years from the date of grant.